Extrapolation of Efficacy and Dose Selection in Pediatrics: A Case Example of Atypical Antipsychotics in Adolescents With Schizophrenia and Bipolar I Disorder

Pediatric labeling information for novel atypical antipsychotics can be significantly delayed as the result of time lag between initial drug approval in adults and the completion of pediatric clinical trials. This delay can lead health care providers to rely on limited evidence‐based literature to m...

Full description

Saved in:
Bibliographic Details
Published in:Journal of clinical pharmacology 2021-06, Vol.61 (S1), p.S117-S124
Main Authors: Kalaria, Shamir N., Farchione, Tiffany R., Uppoor, Ramana, Mehta, Mehul, Wang, Yaning, Zhu, Hao
Format: Article
Language:English
Subjects:
Adolescent
Adolescent Medicine - methods
Antipsychotic Agents - administration & dosage
Antipsychotic Agents - adverse effects
Antipsychotics
bipolar disorder
Bipolar Disorder - drug therapy
Clinical trials
Data Interpretation, Statistical
Dosage
Drug Development
Drug dosages
Drug efficacy
extrapolation
Humans
Mental disorders
Patients
Pediatrics
pediatrics (PED)
Pediatrics - methods
Psychotropic drugs
Schizophrenia
Schizophrenia - drug therapy
Teenagers
Treatment Outcome
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by cdi_FETCH-LOGICAL-c3536-392b99a367345f00b0f7557b01beef71fe6f93dd63e72867b6ed476df1b035563
cites cdi_FETCH-LOGICAL-c3536-392b99a367345f00b0f7557b01beef71fe6f93dd63e72867b6ed476df1b035563
container_end_page S124
container_issue S1
container_start_page S117
container_title Journal of clinical pharmacology
container_volume 61
creator Kalaria, Shamir N.
Farchione, Tiffany R.
Uppoor, Ramana
Mehta, Mehul
Wang, Yaning
Zhu, Hao
description Pediatric labeling information for novel atypical antipsychotics can be significantly delayed as the result of time lag between initial drug approval in adults and the completion of pediatric clinical trials. This delay can lead health care providers to rely on limited evidence‐based literature to make critical therapeutic decisions for pediatric patients. Effective and scientifically justified dosing recommendations are needed to improve treatment outcomes in pediatric patients with schizophrenia and bipolar I disorder. Extrapolation‐based drug development strategies rely on leveraging prior data to reduce evidentiary requirements for newer data in establishing drug efficacy. On January 13, 2020, the US Food and Drug Administration (FDA) released a general advice letter to sponsors highlighting the acceptance of extrapolating efficacy of atypical antipsychotics to pediatric patients. This review provides insight into the FDA's justification for extrapolating efficacy from adult to pediatric patients and provides a rationale for dose selection in pediatric patients with schizophrenia and bipolar I disorder.
doi_str_mv 10.1002/jcph.1836
format article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_2546976285</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2546976285</sourcerecordid><originalsourceid>FETCH-LOGICAL-c3536-392b99a367345f00b0f7557b01beef71fe6f93dd63e72867b6ed476df1b035563</originalsourceid><addsrcrecordid>eNp1kUFv1DAUhC0EokvpgT-ALHEph7R2HNsbbmG70KJKVCoVx8hxnhWvvHGwvWrTH9PfSrJbOCBxeof5Zt5Ig9A7Ss4oIfn5Rg_dGV0y8QItKOd5VghSvEQLQkqa5ZKQI_Qmxg0hVBScvkZHrKBLXpJigZ7WDymowTuVrO-xN3htjNVKj1j1Lb7wEfAtONB72fb4BlqrUrA6fsIVXqlJXz-o7eBgNldpHCa3w1Wf7BBH3fk0obOxar2DqKFPEf-0qcO3urOPfugC9Fbtv322c5GAr_CFjT60EN6iV0a5CCfP9xjdfVn_WF1m19-_Xq2q60wzzkTGyrwpS8WEZAU3hDTESM5lQ2gDYCQ1IEzJ2lYwkPlSyEZAW0jRGtoQxrlgx-j0kDsE_2sHMdVbO3V1TvXgd7HOeSFKKfIln9AP_6Abvwv91G5PkbKUeT5RHw-UDj7GAKYegt2qMNaU1PNo9TxaPY82se-fE3fNFtq_5J-VJuD8ANxbB-P_k-pvq5vLfeRvyWeh6A</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2546099722</pqid></control><display><type>article</type><title>Extrapolation of Efficacy and Dose Selection in Pediatrics: A Case Example of Atypical Antipsychotics in Adolescents With Schizophrenia and Bipolar I Disorder</title><source>Wiley-Blackwell Read &amp; Publish Collection</source><creator>Kalaria, Shamir N. ; Farchione, Tiffany R. ; Uppoor, Ramana ; Mehta, Mehul ; Wang, Yaning ; Zhu, Hao</creator><creatorcontrib>Kalaria, Shamir N. ; Farchione, Tiffany R. ; Uppoor, Ramana ; Mehta, Mehul ; Wang, Yaning ; Zhu, Hao</creatorcontrib><description>Pediatric labeling information for novel atypical antipsychotics can be significantly delayed as the result of time lag between initial drug approval in adults and the completion of pediatric clinical trials. This delay can lead health care providers to rely on limited evidence‐based literature to make critical therapeutic decisions for pediatric patients. Effective and scientifically justified dosing recommendations are needed to improve treatment outcomes in pediatric patients with schizophrenia and bipolar I disorder. Extrapolation‐based drug development strategies rely on leveraging prior data to reduce evidentiary requirements for newer data in establishing drug efficacy. On January 13, 2020, the US Food and Drug Administration (FDA) released a general advice letter to sponsors highlighting the acceptance of extrapolating efficacy of atypical antipsychotics to pediatric patients. This review provides insight into the FDA's justification for extrapolating efficacy from adult to pediatric patients and provides a rationale for dose selection in pediatric patients with schizophrenia and bipolar I disorder.</description><identifier>ISSN: 0091-2700</identifier><identifier>EISSN: 1552-4604</identifier><identifier>DOI: 10.1002/jcph.1836</identifier><identifier>PMID: 34185904</identifier><language>eng</language><publisher>England: Wiley Subscription Services, Inc</publisher><subject>Adolescent ; Adolescent Medicine - methods ; Antipsychotic Agents - administration &amp; dosage ; Antipsychotic Agents - adverse effects ; Antipsychotics ; bipolar disorder ; Bipolar Disorder - drug therapy ; Clinical trials ; Data Interpretation, Statistical ; Dosage ; Drug Development ; Drug dosages ; Drug efficacy ; extrapolation ; Humans ; Mental disorders ; Patients ; Pediatrics ; pediatrics (PED) ; Pediatrics - methods ; Psychotropic drugs ; Schizophrenia ; Schizophrenia - drug therapy ; Teenagers ; Treatment Outcome</subject><ispartof>Journal of clinical pharmacology, 2021-06, Vol.61 (S1), p.S117-S124</ispartof><rights>Published 2021. This article is a U.S. Government work and is in the public domain in the USA.</rights><rights>2021, The American College of Clinical Pharmacology</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c3536-392b99a367345f00b0f7557b01beef71fe6f93dd63e72867b6ed476df1b035563</citedby><cites>FETCH-LOGICAL-c3536-392b99a367345f00b0f7557b01beef71fe6f93dd63e72867b6ed476df1b035563</cites><orcidid>0000-0001-7980-4236</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27924,27925</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/34185904$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Kalaria, Shamir N.</creatorcontrib><creatorcontrib>Farchione, Tiffany R.</creatorcontrib><creatorcontrib>Uppoor, Ramana</creatorcontrib><creatorcontrib>Mehta, Mehul</creatorcontrib><creatorcontrib>Wang, Yaning</creatorcontrib><creatorcontrib>Zhu, Hao</creatorcontrib><title>Extrapolation of Efficacy and Dose Selection in Pediatrics: A Case Example of Atypical Antipsychotics in Adolescents With Schizophrenia and Bipolar I Disorder</title><title>Journal of clinical pharmacology</title><addtitle>J Clin Pharmacol</addtitle><description>Pediatric labeling information for novel atypical antipsychotics can be significantly delayed as the result of time lag between initial drug approval in adults and the completion of pediatric clinical trials. This delay can lead health care providers to rely on limited evidence‐based literature to make critical therapeutic decisions for pediatric patients. Effective and scientifically justified dosing recommendations are needed to improve treatment outcomes in pediatric patients with schizophrenia and bipolar I disorder. Extrapolation‐based drug development strategies rely on leveraging prior data to reduce evidentiary requirements for newer data in establishing drug efficacy. On January 13, 2020, the US Food and Drug Administration (FDA) released a general advice letter to sponsors highlighting the acceptance of extrapolating efficacy of atypical antipsychotics to pediatric patients. This review provides insight into the FDA's justification for extrapolating efficacy from adult to pediatric patients and provides a rationale for dose selection in pediatric patients with schizophrenia and bipolar I disorder.</description><subject>Adolescent</subject><subject>Adolescent Medicine - methods</subject><subject>Antipsychotic Agents - administration &amp; dosage</subject><subject>Antipsychotic Agents - adverse effects</subject><subject>Antipsychotics</subject><subject>bipolar disorder</subject><subject>Bipolar Disorder - drug therapy</subject><subject>Clinical trials</subject><subject>Data Interpretation, Statistical</subject><subject>Dosage</subject><subject>Drug Development</subject><subject>Drug dosages</subject><subject>Drug efficacy</subject><subject>extrapolation</subject><subject>Humans</subject><subject>Mental disorders</subject><subject>Patients</subject><subject>Pediatrics</subject><subject>pediatrics (PED)</subject><subject>Pediatrics - methods</subject><subject>Psychotropic drugs</subject><subject>Schizophrenia</subject><subject>Schizophrenia - drug therapy</subject><subject>Teenagers</subject><subject>Treatment Outcome</subject><issn>0091-2700</issn><issn>1552-4604</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2021</creationdate><recordtype>article</recordtype><recordid>eNp1kUFv1DAUhC0EokvpgT-ALHEph7R2HNsbbmG70KJKVCoVx8hxnhWvvHGwvWrTH9PfSrJbOCBxeof5Zt5Ig9A7Ss4oIfn5Rg_dGV0y8QItKOd5VghSvEQLQkqa5ZKQI_Qmxg0hVBScvkZHrKBLXpJigZ7WDymowTuVrO-xN3htjNVKj1j1Lb7wEfAtONB72fb4BlqrUrA6fsIVXqlJXz-o7eBgNldpHCa3w1Wf7BBH3fk0obOxar2DqKFPEf-0qcO3urOPfugC9Fbtv322c5GAr_CFjT60EN6iV0a5CCfP9xjdfVn_WF1m19-_Xq2q60wzzkTGyrwpS8WEZAU3hDTESM5lQ2gDYCQ1IEzJ2lYwkPlSyEZAW0jRGtoQxrlgx-j0kDsE_2sHMdVbO3V1TvXgd7HOeSFKKfIln9AP_6Abvwv91G5PkbKUeT5RHw-UDj7GAKYegt2qMNaU1PNo9TxaPY82se-fE3fNFtq_5J-VJuD8ANxbB-P_k-pvq5vLfeRvyWeh6A</recordid><startdate>202106</startdate><enddate>202106</enddate><creator>Kalaria, Shamir N.</creator><creator>Farchione, Tiffany R.</creator><creator>Uppoor, Ramana</creator><creator>Mehta, Mehul</creator><creator>Wang, Yaning</creator><creator>Zhu, Hao</creator><general>Wiley Subscription Services, Inc</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7QP</scope><scope>7QR</scope><scope>7T5</scope><scope>7TK</scope><scope>7TM</scope><scope>8FD</scope><scope>FR3</scope><scope>H94</scope><scope>K9.</scope><scope>NAPCQ</scope><scope>P64</scope><scope>RC3</scope><scope>7X8</scope><orcidid>https://orcid.org/0000-0001-7980-4236</orcidid></search><sort><creationdate>202106</creationdate><title>Extrapolation of Efficacy and Dose Selection in Pediatrics: A Case Example of Atypical Antipsychotics in Adolescents With Schizophrenia and Bipolar I Disorder</title><author>Kalaria, Shamir N. ; Farchione, Tiffany R. ; Uppoor, Ramana ; Mehta, Mehul ; Wang, Yaning ; Zhu, Hao</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c3536-392b99a367345f00b0f7557b01beef71fe6f93dd63e72867b6ed476df1b035563</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2021</creationdate><topic>Adolescent</topic><topic>Adolescent Medicine - methods</topic><topic>Antipsychotic Agents - administration &amp; dosage</topic><topic>Antipsychotic Agents - adverse effects</topic><topic>Antipsychotics</topic><topic>bipolar disorder</topic><topic>Bipolar Disorder - drug therapy</topic><topic>Clinical trials</topic><topic>Data Interpretation, Statistical</topic><topic>Dosage</topic><topic>Drug Development</topic><topic>Drug dosages</topic><topic>Drug efficacy</topic><topic>extrapolation</topic><topic>Humans</topic><topic>Mental disorders</topic><topic>Patients</topic><topic>Pediatrics</topic><topic>pediatrics (PED)</topic><topic>Pediatrics - methods</topic><topic>Psychotropic drugs</topic><topic>Schizophrenia</topic><topic>Schizophrenia - drug therapy</topic><topic>Teenagers</topic><topic>Treatment Outcome</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Kalaria, Shamir N.</creatorcontrib><creatorcontrib>Farchione, Tiffany R.</creatorcontrib><creatorcontrib>Uppoor, Ramana</creatorcontrib><creatorcontrib>Mehta, Mehul</creatorcontrib><creatorcontrib>Wang, Yaning</creatorcontrib><creatorcontrib>Zhu, Hao</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Calcium &amp; Calcified Tissue Abstracts</collection><collection>Chemoreception Abstracts</collection><collection>Immunology Abstracts</collection><collection>Neurosciences Abstracts</collection><collection>Nucleic Acids Abstracts</collection><collection>Technology Research Database</collection><collection>Engineering Research Database</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>ProQuest Health &amp; Medical Complete (Alumni)</collection><collection>Nursing &amp; Allied Health Premium</collection><collection>Biotechnology and BioEngineering Abstracts</collection><collection>Genetics Abstracts</collection><collection>MEDLINE - Academic</collection><jtitle>Journal of clinical pharmacology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Kalaria, Shamir N.</au><au>Farchione, Tiffany R.</au><au>Uppoor, Ramana</au><au>Mehta, Mehul</au><au>Wang, Yaning</au><au>Zhu, Hao</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Extrapolation of Efficacy and Dose Selection in Pediatrics: A Case Example of Atypical Antipsychotics in Adolescents With Schizophrenia and Bipolar I Disorder</atitle><jtitle>Journal of clinical pharmacology</jtitle><addtitle>J Clin Pharmacol</addtitle><date>2021-06</date><risdate>2021</risdate><volume>61</volume><issue>S1</issue><spage>S117</spage><epage>S124</epage><pages>S117-S124</pages><issn>0091-2700</issn><eissn>1552-4604</eissn><abstract>Pediatric labeling information for novel atypical antipsychotics can be significantly delayed as the result of time lag between initial drug approval in adults and the completion of pediatric clinical trials. This delay can lead health care providers to rely on limited evidence‐based literature to make critical therapeutic decisions for pediatric patients. Effective and scientifically justified dosing recommendations are needed to improve treatment outcomes in pediatric patients with schizophrenia and bipolar I disorder. Extrapolation‐based drug development strategies rely on leveraging prior data to reduce evidentiary requirements for newer data in establishing drug efficacy. On January 13, 2020, the US Food and Drug Administration (FDA) released a general advice letter to sponsors highlighting the acceptance of extrapolating efficacy of atypical antipsychotics to pediatric patients. This review provides insight into the FDA's justification for extrapolating efficacy from adult to pediatric patients and provides a rationale for dose selection in pediatric patients with schizophrenia and bipolar I disorder.</abstract><cop>England</cop><pub>Wiley Subscription Services, Inc</pub><pmid>34185904</pmid><doi>10.1002/jcph.1836</doi><tpages>8</tpages><orcidid>https://orcid.org/0000-0001-7980-4236</orcidid></addata></record>
fulltext fulltext
identifier ISSN: 0091-2700
ispartof Journal of clinical pharmacology, 2021-06, Vol.61 (S1), p.S117-S124
issn 0091-2700
1552-4604
language eng
recordid cdi_proquest_miscellaneous_2546976285
source Wiley-Blackwell Read & Publish Collection
subjects Adolescent
Adolescent Medicine - methods
Antipsychotic Agents - administration & dosage
Antipsychotic Agents - adverse effects
Antipsychotics
bipolar disorder
Bipolar Disorder - drug therapy
Clinical trials
Data Interpretation, Statistical
Dosage
Drug Development
Drug dosages
Drug efficacy
extrapolation
Humans
Mental disorders
Patients
Pediatrics
pediatrics (PED)
Pediatrics - methods
Psychotropic drugs
Schizophrenia
Schizophrenia - drug therapy
Teenagers
Treatment Outcome
title Extrapolation of Efficacy and Dose Selection in Pediatrics: A Case Example of Atypical Antipsychotics in Adolescents With Schizophrenia and Bipolar I Disorder
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-29T12%3A05%3A07IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Extrapolation%20of%20Efficacy%20and%20Dose%20Selection%20in%20Pediatrics:%20A%20Case%20Example%20of%20Atypical%20Antipsychotics%20in%20Adolescents%20With%20Schizophrenia%20and%20Bipolar%20I%20Disorder&rft.jtitle=Journal%20of%20clinical%20pharmacology&rft.au=Kalaria,%20Shamir%20N.&rft.date=2021-06&rft.volume=61&rft.issue=S1&rft.spage=S117&rft.epage=S124&rft.pages=S117-S124&rft.issn=0091-2700&rft.eissn=1552-4604&rft_id=info:doi/10.1002/jcph.1836&rft_dat=%3Cproquest_cross%3E2546976285%3C/proquest_cross%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c3536-392b99a367345f00b0f7557b01beef71fe6f93dd63e72867b6ed476df1b035563%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=2546099722&rft_id=info:pmid/34185904&rfr_iscdi=true